Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment.

IF 1.5 4区医学 Q3 DERMATOLOGY

Annals of Dermatology Pub Date : 2023-06-01 DOI:10.5021/ad.22.167

Hyunsun Park, Jung Eun Kim, Jee Woong Choi, Do Young Kim, Yong Hyun Jang, Young Lee, Jiehyun Jeon, Hyun-Tae Shin, Min Sung Kim, Jung Won Shin, Sung Bin Cho, Bark-Lynn Lew, Gwang Seong Choi

{"title":"Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment.","authors":"Hyunsun Park, Jung Eun Kim, Jee Woong Choi, Do Young Kim, Yong Hyun Jang, Young Lee, Jiehyun Jeon, Hyun-Tae Shin, Min Sung Kim, Jung Won Shin, Sung Bin Cho, Bark-Lynn Lew, Gwang Seong Choi","doi":"10.5021/ad.22.167","DOIUrl":null,"url":null,"abstract":"Background: Alopecia areata (AA) is a chronic disease with an unpredictable course and can have a severe psychological impact on an individual.Objective: To provide evidence and consensus-based statements regarding the treatment of patients with AA in Korea.Methods: We searched for relevant studies from inception to May 2021 regarding the systemic treatment of AA. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statement, and an agreement of 75% or greater was considered as having reached consensus.Results: Current evidence supports the efficacy of systemic corticosteroids, oral cyclosporine monotherapy or combination with systemic corticosteroids, and oral Janus kinase inhibitors in severe AA patients. Systemic steroids may be considered for pediatric patients with severe AA. A consensus was achieved in three out of nine (33.3%), and one out of three (33.3%) statements pertaining to systemic treatment in adult and pediatric AA, respectively.Conclusion: The present study produced up-to-date, evidence-based treatment guidelines for AA associated with the consensus obtained by experts based on the Korean healthcare system.","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"35 3","pages":"205-216"},"PeriodicalIF":1.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/b7/ad-35-205.PMC10258553.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5021/ad.22.167","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alopecia areata (AA) is a chronic disease with an unpredictable course and can have a severe psychological impact on an individual.

Objective: To provide evidence and consensus-based statements regarding the treatment of patients with AA in Korea.

Methods: We searched for relevant studies from inception to May 2021 regarding the systemic treatment of AA. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statement, and an agreement of 75% or greater was considered as having reached consensus.

Results: Current evidence supports the efficacy of systemic corticosteroids, oral cyclosporine monotherapy or combination with systemic corticosteroids, and oral Janus kinase inhibitors in severe AA patients. Systemic steroids may be considered for pediatric patients with severe AA. A consensus was achieved in three out of nine (33.3%), and one out of three (33.3%) statements pertaining to systemic treatment in adult and pediatric AA, respectively.

Conclusion: The present study produced up-to-date, evidence-based treatment guidelines for AA associated with the consensus obtained by experts based on the Korean healthcare system.

Abstract Image

查看原文本刊更多论文

韩国脱发患者管理指南：第二部分：系统治疗。

背景：斑秃（AA）是一种慢性疾病，病程难以预测，会对患者造成严重的心理影响：目的：提供有关韩国 AA 患者治疗的证据和基于共识的声明：方法：我们搜索了从开始到 2021 年 5 月有关 AA 系统治疗的相关研究。我们还编写了基于证据的建议。根据建议的强度对每项声明的证据进行了分级和分类。韩国毛发研究学会（KHRS）的毛发专家对声明进行投票，75%或更高的同意率被视为达成共识：目前的证据支持全身性皮质类固醇激素、口服环孢素单药治疗或与全身性皮质类固醇激素联合治疗以及口服 Janus 激酶抑制剂对严重 AA 患者的疗效。严重 AA 的儿童患者可考虑使用全身性类固醇。关于成人和儿童 AA 的全身治疗，9 项声明中有 3 项（33.3%）达成了共识，3 项声明中有 1 项（33.3%）达成了共识：本研究为AA制定了最新的循证治疗指南，专家们在韩国医疗系统的基础上达成了共识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Dermatology 医学-皮肤病学

CiteScore

1.60

自引率

6.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Annals of Dermatology (Ann Dermatol) is the official peer-reviewed publication of the Korean Dermatological Association and the Korean Society for Investigative Dermatology. Since 1989, Ann Dermatol has contributed as a platform for communicating the latest research outcome and recent trend of dermatology in Korea and all over the world. Ann Dermatol seeks for ameliorated understanding of skin and skin-related disease for clinicians and researchers. Ann Dermatol deals with diverse skin-related topics from laboratory investigations to clinical outcomes and invites review articles, original articles, case reports, brief reports and items of correspondence. Ann Dermatol is interested in contributions from all countries in which good and advanced research is carried out. Ann Dermatol willingly recruits well-organized and significant manuscripts with proper scope throughout the world.